Skip to main content
. 2021 Oct 29;18(2):285–292. doi: 10.5114/aoms/143476

Figure 2.

Figure 2

Proportion of patients achieving LDL-C goals. A – Week 24. B – Week 48, according to adherence to alirocumab* (mITT population)

*Adherence to alirocumab treatment was assessed according to patients’ diary data over the duration of the trial; percent adherence was defined as the number of injections received divided by the number of theoretical injections to be received during the study period multiplied by 100, with the number of theoretical injections defined as the last injection date minus the first injection date divided by 14. LDL-C – low-density lipoprotein cholesterol, mITT – modified intention-to-treat.